These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15484216)

  • 1. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
    Buesa JM; Losa R; Fernández A; Sierra M; Esteban E; Díaz A; López-Pousa A; Fra J
    Cancer; 2004 Nov; 101(10):2261-9. PubMed ID: 15484216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
    Losa R; Fra J; López-Pousa A; Sierra M; Goitia A; Uña E; Nadal R; Del Muro JG; Gión M; Maurel J; Escudero P; Esteban E; Buesa JM
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):251-9. PubMed ID: 16736150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
    García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
    J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
    Baka S; Manegold C; Buchholz E; Schott-von-Römer K; Lorigan P; Nagel S; Blackhall F; Aschroft L; Thatcher N
    Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
    Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
    Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
    Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
    Patel SR; Gandhi V; Jenkins J; Papadopolous N; Burgess MA; Plager C; Plunkett W; Benjamin RS
    J Clin Oncol; 2001 Aug; 19(15):3483-9. PubMed ID: 11481354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes.
    Salman HS; Tanaka K; Sparano JA
    Clin Breast Cancer; 2002 Jan; 2(4):299-303. PubMed ID: 11899362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
    Elias AD; Antman KH
    Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
    Tassinari D; Drudi G; Panzini I; Pasini G; Arcangeli V; Fochessati F; Gianni L; Mianulli AM; Oliverio G; Pasquini E; Sartori S; Ravaioli A
    Int J Clin Oncol; 2001 Dec; 6(6):279-83. PubMed ID: 11828946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
    Shan YS; Lin PW
    Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
    Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Stagg MP; Fontenot MF; Buller EJ; Rainey JM
    Am J Clin Oncol; 2000 Feb; 23(1):78-82. PubMed ID: 10683085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
    Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
    J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
    López-Pousa A; Losa R; Martín J; Maurel J; Fra J; Sierra M; Casado A; García Del Muro J; Poveda A; Balañá C; Martínez-Trufero J; Esteban E; Buesa JM
    Br J Cancer; 2006 Jun; 94(12):1797-802. PubMed ID: 16721358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.